Immune-related adverse events with resumed anti-PD-1 therapy

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2017年 / 1676卷 / 1期
关键词：
D O I：
10.1007/s40278-017-37992-3
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4 / 4
相关论文
共 50 条
  • [41] The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events
    Fujisaki, Toshiya
    Watanabe, Satoshi
    Ota, Takeshi
    Kushiro, Kohei
    Sato, Yusuke
    Takahashi, Miho
    Ohtsubo, Aya
    Shoji, Satoshi
    Nozaki, Koichiro
    Ichikawa, Kosuke
    Hokari, Satoshi
    Kondo, Rie
    Miyabayashi, Takao
    Abe, Tetsuya
    Miura, Satoru
    Tanaka, Hiroshi
    Okajima, Masaaki
    Terada, Masaki
    Matsumoto, Naoya
    Ishida, Takashi
    Iwashima, Akira
    Sato, Kazuhiro
    Yoshizawa, Hirohisa
    Aoki, Nobumasa
    Hayashi, Masachika
    Ohshima, Yasuyoshi
    Koya, Toshiyuki
    Kikuchi, Toshiaki
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [42] Soluble PD-L1 predicts tumor response and immune-related adverse events in patients with advanced melanoma treated with anti-PD-1 antibodies
    Oya, Kazumasa
    Nakamura, Yoshiyuki
    Shen, Larina Tzu-Wei
    Ishizuki, Shoichiro
    Matsusaka, Satoshi
    Fujisawa, Yasuhiro
    [J]. JOURNAL OF DERMATOLOGY, 2024, 51 (06): : 807 - 815
  • [43] Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma
    Borgers, Jessica S. W.
    van Wesemael, Tineke J.
    Gelderman, Kyra A.
    Rispens, Theo
    Verdegaal, Els M. E.
    Moes, Dirk J. A. R.
    Korse, Catharina M.
    Kapiteijn, Ellen
    Welters, Marij J. P.
    van der Burg, Sjoerd H.
    van Houdt, Winan J.
    van Thienen, Johannes, V
    Haanen, John B. A. G.
    van der Woude, Diane
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (06)
  • [44] The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
    Chiao-En Wu
    Chan-Keng Yang
    Meng-Ting Peng
    Pei-Wei Huang
    Ching-Fu Chang
    Kun-Yun Yeh
    Chun-Bing Chen
    Chih-Liang Wang
    Chao-Wei Hsu
    I-Wen Chen
    Cheng-Tao Lin
    Shir-Hwa Ueng
    Gigin Lin
    Yu-Fen Lin
    Chi-Yuan Cheng
    John Wen-Cheng Chang
    [J]. BMC Cancer, 20
  • [45] The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
    Wu, Chiao-En
    Yang, Chan-Keng
    Peng, Meng-Ting
    Huang, Pei-Wei
    Chang, Ching-Fu
    Yeh, Kun-Yun
    Chen, Chun-Bing
    Wang, Chih-Liang
    Hsu, Chao-Wei
    Chen, I-Wen
    Lin, Cheng-Tao
    Ueng, Shir-Hwa
    Lin, Gigin
    Lin, Yu-Fen
    Cheng, Chi-Yuan
    Chang, John Wen-Cheng
    [J]. BMC CANCER, 2020, 20 (01)
  • [46] Profiling Immune-Related Adverse Events (irAEs) in Patients with Anti-PD-1 for Advanced Non-Small Cell Lung Cancer
    Toi, Y.
    Sugawara, S.
    Aso, M.
    Tsurumi, K.
    Ono, K.
    Sugisaka, J.
    Shimizu, H.
    Ono, H.
    Domeki, Y.
    Aiba, T.
    Kawana, S.
    Saito, R.
    Terayama, K.
    Kawashima, Y.
    Nakamura, A.
    Yamanda, S.
    Kimura, Y.
    Honda, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S598 - S599
  • [47] Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma
    Goodman, Rachel S.
    Lawless, Aleigha
    Woodford, Rachel
    Fa'ak, Faisal
    Tipirneni, Asha
    Patrinely, J. Randall
    Yeoh, Hui Ling
    Rapisuwon, Suthee
    Haydon, Andrew
    Osman, Iman
    Mehnert, Janice M.
    Long, Georgina V.
    Sullivan, Ryan J.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Johnson, Douglas B.
    [J]. JAMA NETWORK OPEN, 2023, 6 (08) : E2327145
  • [48] Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors
    Subashini Sharon Gnanendran
    Lauren Maree Turner
    James Austin Miller
    Shelley Ji Eun Hwang
    Andrew Charles Miller
    [J]. Current Treatment Options in Oncology, 2020, 21
  • [49] Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma
    Goodman, Rachel S.
    Lawless, Aleigha
    Woodford, Rachel
    Fa'ak, Faisal
    Tipirneni, Asha
    Patrinely, James Randall
    Yeoh, Hui-Ling
    Rapisuwon, Suthee
    Haydon, Andrew
    Osman, Iman
    Mehnert, Janice M.
    Long, Georgina V.
    Sullivan, Ryan J.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Johnson, Douglas Buckner
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors
    Gnanendran, Subashini Sharon
    Turner, Lauren Maree
    Miller, James Austin
    Hwang, Shelley Ji Eun
    Miller, Andrew Charles
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (04)
12345